Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) disclosed that Louis E. Tamayo intends to sell common stock under Rule 144 through Fidelity Brokerage Services LLC. The planned sale covers 4,117 shares of common stock on NASDAQ, arising from restricted stock vesting, with part of the sale used to satisfy a tax obligation from a vested equity award. In the prior three months, Tamayo sold 4,641 shares of common stock for total proceeds of 20,814.89.

Key Figures

Shares to be sold: 4,117 shares Approximate market value of planned sale: 20,202.53 Shares outstanding of class: 82,046,255 shares +2 more

5 metrics

Shares to be sold 4,117 shares Common stock planned for sale under Rule 144

Approximate market value of planned sale 20,202.53 Value associated with 4,117 shares of common stock

Shares outstanding of class 82,046,255 shares Common stock of the same class as of the filing data

Shares sold in past 3 months 4,641 shares Common stock sold by Louis E. Tamayo on 07/01/2026

Proceeds from past 3-month sale 20,814.89 Aggregate proceeds for 4,641 common shares sold on 07/01/2026

Key Terms

Rule 144, Restricted Stock Vesting, equity award distribution, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 08/17/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

equity award distribution financial

"resulting from the settlement of a vested equity award distribution."

attorney-in-fact regulatory

"as attorney-in-fact for Louis Tamayo"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for LXEO disclose about planned share sales?

The Form 144 notice states that 4,117 shares of Lexeo Therapeutics, Inc. common stock are planned for sale on NASDAQ. These shares relate to restricted stock vesting, and the sale includes an amount to cover a tax obligation from a vested equity award.

Who is selling Lexeo Therapeutics (LXEO) shares in this Form 144 filing?

The notice covers sales for Louis E. Tamayo, with Fidelity Brokerage Services LLC acting as broker and signing as attorney-in-fact. Tamayo’s address is listed at Lexeo’s New York office, indicating the transaction involves a company-affiliated individual’s holdings.

How many LXEO shares has Louis E. Tamayo sold in the past three months?

Over the past three months, Louis E. Tamayo sold 4,641 shares of Lexeo Therapeutics common stock. Those shares were sold on 07/01/2026 for aggregate proceeds of 20,814.89, as reported in the recent Rule 144 notice.

What is the purpose of the LXEO share sale related to the vested equity award?

The filing explains that the sale includes an amount necessary to cover a tax obligation created by settlement of a vested equity award distribution. This means part of the planned 4,117-share sale is specifically intended to satisfy tax liabilities.

What key dates are associated with the LXEO Form 144 filing for Louis E. Tamayo?

The notice date is 08/18/2026, and the securities to be sold relate to restricted stock vesting dated 08/17/2026. A prior reported sale of 4,641 common shares occurred on 07/01/2026, according to the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 03:09 PM Accepted by SEC EDGAR 08/18/2026 - 03:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002083206
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Lexeo Therapeutics, Inc.
SEC File Number	001-41855
Address of Issuer	345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NEW YORK 10010
Phone	(212) 547-9879
Name of Person for Whose Account the Securities are To Be Sold	Tamayo Louis Edward
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4117	20202.53	82046255	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/17/2026	Restricted Stock Vesting	Issuer			4117	08/17/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Louis E. Tamayo 345 Park Avenue South Floor 6 New York NY 10010	Common	07/01/2026	4641	20814.89

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Louis Tamayo
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)